T. Rowe Price Associates
NEO icon

T. Rowe Price Associates’s NeoGenomics NEO Stock Holding History

T. Rowe Price Associates’s Portfolio NEO Stock Details NEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.16M Buy
156,118
+32,188
+26% +$339K ﹤0.01% 2082
2025
Q4 		$1.46M Buy
123,930
+5,001
+4% +$54K ﹤0.01% 1909
2025
Q3 		$919K Buy
118,929
+5,837
+5% +$40.9K ﹤0.01% 2113
2025
Q2 		$827K Buy
113,092
+8,130
+8% +$65.6K ﹤0.01% 2070
2025
Q1 		$997K Buy
104,962
+13,388
+15% +$167K ﹤0.01% 1960
2024
Q4 		$1.51M Sell
91,574
-340,966
-79% -$5.3M ﹤0.01% 1780
2024
Q3 		$6.38M Sell
432,540
-156,054
-27% -$2.44M ﹤0.01% 1230
2024
Q2 		$8.16M Sell
588,594
-56,898
-9% -$807K ﹤0.01% 1138
2024
Q1 		$10.1M Buy
645,492
+4,528
+0.7% +$69.9K ﹤0.01% 1106
2023
Q4 		$10.4M Buy
640,964
+46,967
+8% +$769K ﹤0.01% 1084
2023
Q3 		$7.31M Buy
593,997
+11,309
+2% +$168K ﹤0.01% 1119
2023
Q2 		$9.37M Buy
582,688
+252,988
+77% +$4.17M ﹤0.01% 1087
2023
Q1 		$5.74M Buy
329,700
+1,358
+0.4% +$19.3K ﹤0.01% 1153
2022
Q4 		$3.03M Sell
328,342
-399,246
-55% -$3.72M ﹤0.01% 1318
2022
Q3 		$6.27M Sell
727,588
-844,425
-54% -$8.39M ﹤0.01% 1161
2022
Q2 		$12.8M Buy
1,572,013
+5,076
+0.3% +$48.5K ﹤0.01% 1278
2022
Q1 		$19M Buy
1,566,937
+16,655
+1% +$350K ﹤0.01% 1236
2021
Q4 		$52.9M Sell
1,550,282
-1,220
-0.1% -$47.8K ﹤0.01% 986
2021
Q3 		$74.8M Sell
1,551,502
-7,545
-0.5% -$349K 0.01% 873
2021
Q2 		$70.4M Buy
1,559,047
+6,811
+0.4% +$302K 0.01% 913
2021
Q1 		$74.9M Buy
1,552,236
+189,930
+14% +$9.89M 0.01% 865
2020
Q4 		$73.3M Buy
1,362,306
+213,574
+19% +$9.65M 0.01% 828
2020
Q3 		$42.4M Buy
1,148,732
+135,118
+13% +$5.02M ﹤0.01% 928
2020
Q2 		$31.4M Buy
1,013,614
+74,071
+8% +$2.05M ﹤0.01% 1001
2020
Q1 		$25.9M Buy
939,543
+881,841
+1,528% +$26.4M ﹤0.01% 988
2019
Q4 		$1.69M Buy
57,702
+38,699
+204% +$922K ﹤0.01% 1670
2019
Q3 		$363K Buy
19,003
+601
+3% +$14.1K ﹤0.01% 2219
2019
Q2 		$404K Buy
18,402
+7,077
+62% +$155K ﹤0.01% 2193
2019
Q1 		$232K Buy
11,325
+468
+4% +$8.13K ﹤0.01% 2368
2018
Q4 		$137K Buy
10,857
+108
+1% +$1.61K ﹤0.01% 2463
2018
Q3 		$165K Buy
10,749
+431
+4% +$5.96K ﹤0.01% 2488
2018
Q2 		$135K Buy
10,318
+62
+0.6% +$682 ﹤0.01% 2502
2018
Q1 		$84K Buy
10,256
+110
+1% +$891 ﹤0.01% 2510
2017
Q4 		$90K Sell
10,146
-4,600
-31% -$42.4K ﹤0.01% 2518
2017
Q3 		$164K Hold
14,746
– – ﹤0.01% 2443
2017
Q2 		$132K Buy
14,746
+2,100
+17% +$16.7K ﹤0.01% 2452
2017
Q1 		$100K Buy
+12,646
New +$103K ﹤0.01% 2488

Other funds holding NEO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $2.23B AUM 12.38% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

T. Rowe Price Associates's NEO Position: Q1 2026 in Review

T. Rowe Price Associates increased its NeoGenomics (NEO) stake by 26% in Q1 2026, buying an estimated $339K and bringing the position to 156,118 shares worth $1.16M. The position accounts for ﹤0.01% of the portfolio, ranked #2082.

T. Rowe Price Associates first reported a position in NEO in Q1 2017 and has held it in 37 quarters since. The position peaked at $74.9M in Q1 2021. 253 funds tracked by Wall St. Rank hold NEO as of Q1 2026.

  • T. Rowe Price Associates held 156,118 shares of NeoGenomics worth $1.16M as of Q1 2026.
  • T. Rowe Price Associates bought 32,188 NeoGenomics shares in Q1 2026, an estimated $339K.
  • NeoGenomics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #2082 holding.
  • T. Rowe Price Associates first reported a position in NeoGenomics in Q1 2017 and has held it in 37 quarters since.
  • T. Rowe Price Associates's NeoGenomics position peaked at $74.9M in Q1 2021.
  • 253 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.